Request Demo
Recent blog posts
Latest Hotspot
8 min read
NCT07505303 Semaglutide (Novo Nordisk) Weight Loss Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07505303 clinical trial report covering Semaglutide (Novo Nordisk), Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07505160 Lisaftoclax Acute Myeloid Leukemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07505160 clinical trial report covering Lisaftoclax, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07505849 Zanubrutinib Follicular Lymphoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07505849 clinical trial report covering Zanubrutinib, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07504601 Hydroxynorketamine Acute Pain Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07504601 clinical trial report covering Hydroxynorketamine, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07504588 Bevacizumab Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07504588 clinical trial report covering Bevacizumab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07507825 Omacetaxine Mepesuccinate Acute Myeloid Leukemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07507825 clinical trial report covering Omacetaxine Mepesuccinate, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07507513 SSGJ-627 Colitis, Ulcerative Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07507513 clinical trial report covering SSGJ-627, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
CTR20261164 TAN-118 Ulcerative colitis, active moderate Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
CTR20261164 clinical trial report covering TAN-118, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07507916 Serplulimab Gastroesophageal junction adenocarcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07507916 clinical trial report covering Serplulimab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07507318 Chidamide Diffuse Large B-Cell Lymphoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07507318 clinical trial report covering Chidamide, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07507526 Tunlametinib stomach adenocarcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07507526 clinical trial report covering Tunlametinib, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07507188 Amivantamab-VMJM EGFR-mutated non-small Cell Lung Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07507188 clinical trial report covering Amivantamab-VMJM, Phase 2, endpoints, sponsor, geography, readout timing and development white space.